1. Home
  2. UONEK vs SKYE Comparison

UONEK vs SKYE Comparison

Compare UONEK & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Urban One Inc. Class D

UONEK

Urban One Inc. Class D

N/A

Current Price

$5.06

Market Cap

26.8M

ML Signal

N/A

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.72

Market Cap

24.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UONEK
SKYE
Founded
1980
2012
Country
United States
United States
Employees
1272
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.8M
24.2M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
UONEK
SKYE
Price
$5.06
$0.72
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$15.00
AVG Volume (30 Days)
16.8K
190.3K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$0.57
52 Week High
$9.38
$5.75

Technical Indicators

Market Signals
Indicator
UONEK
SKYE
Relative Strength Index (RSI) 43.09 41.53
Support Level $4.75 $0.71
Resistance Level $6.12 $0.83
Average True Range (ATR) 0.64 0.08
MACD -0.02 -0.02
Stochastic Oscillator 17.14 5.55

Price Performance

Historical Comparison
UONEK
SKYE

About UONEK Urban One Inc. Class D

Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: